Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Spelman

Showing results (251-260 of 266) with videos related to

Pageof 27
Sort By:
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
Neurology|October 6, 2021
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisSteve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Current Epidemiology and Clinical Features of Cryptococcus Infection in Patients Without Human Immunodeficiency Virus: A Multicenter Study in 46 Hospitals in Australia and New ZealandJulien Coussement, Christopher H Heath, Matthew B Roberts, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2024
Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New ZealandJulien Coussement, Christopher H Heath, Matthew B Roberts, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeveritySteve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 15, 2020
COVID-19 in people with multiple sclerosis: A global data sharing initiativeLiesbet M Peeters, Tina Parciak, Clare Walton, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Pageof 27

Showing results (251-260 of 266) with videos related to

Sort By:
Pageof 27
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
Neurology|October 6, 2021
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisSteve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Current Epidemiology and Clinical Features of Cryptococcus Infection in Patients Without Human Immunodeficiency Virus: A Multicenter Study in 46 Hospitals in Australia and New ZealandJulien Coussement, Christopher H Heath, Matthew B Roberts, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2024
Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New ZealandJulien Coussement, Christopher H Heath, Matthew B Roberts, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeveritySteve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 15, 2020
COVID-19 in people with multiple sclerosis: A global data sharing initiativeLiesbet M Peeters, Tina Parciak, Clare Walton, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Pageof 27